{"nct_id":"NCT04960709","title":"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-10","start_date":"2021-08-05","start_date_type":"ACTUAL","primary_completion_date":"2026-04-30","primary_completion_date_type":"ESTIMATED","completion_date":"2028-09-08","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}